Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Extra Pale who wrote (600)	3/14/2005 5:28:01 PM
From: tom pope	Respond to of 946

I haven't owned LGND for ages, and the price action is horrible, but it seems to me that the upside from a successful Targretin outcome outweighs the downside of a failure. I started building a position last week, at an average of around 8.85

To: Extra Pale who wrote (600)	3/14/2005 5:30:11 PM
From: IRWIN JAMES FRANKEL	Read Replies (2) \| Respond to of 946

>> Imagine what approval of Xyotax would have/will increase CTIC's market cap. Let's imagine world peace too.* Each seem equally fanciful at this point. After a brief plateau (3 days at 5+) CTIC is daily setting lower lows and lower highs. There may be a time to buy - but we are not there yet, for my money. Maybe at 2. ij * I don't mean to be harsh. But Bianco's rose colored glasses have pulled in lots of buyers who have been hurt. I am sorry for that. But imagining $10B market cap stocks and comparing DNA to CTIC is TOO much - IMHO.